BioCentury | Jun 20, 2017
Distillery Therapeutics

Cancer

...α-synuclein, in Phase I to treat PD. Neuropore Therapies Inc. and UCB S.A. have NPT200-11 (UCB1332...
BioCentury | Mar 28, 2016
Clinical News

UCB1332: Phase I data

...360 and 480 mg oral NPT200-11 were well tolerated. UCB has exclusive, worldwide rights to NPT200-11...
...Neuropore Therapies Inc. , San Diego, Calif. UCB Group (Euronext:UCB), Brussels, Belgium Product: UCB1332 , NPT200-11...
BioCentury | Sep 7, 2015
Strategy

Back to School 2015: Changing the subject

No longer content with a walk-on role as research subjects, and empowered by access to more information and the necessity of shouldering a bigger share of the healthcare bill, patients are demanding a speaking role...
BioCentury | Jan 17, 2015
Company News

UCB licenses Neuropore's PD compound

...Unterach, Austria), granted UCB Group (Euronext:UCB) an exclusive, worldwide license to preclinical Parkinson's disease candidate NPT200-11...
...up to $460 in development, regulatory and sales milestones, plus royalties. The companies will co-develop NPT200-11...
Items per page:
1 - 4 of 4